Epidemiology of neurological diseases in elderly people: what did we learn from the Rotterdam Study?

Lancet Neurology

Volumn 5, Issue 6, 2006, Pages 545-550

  Hofman, Albert ^a   de Jong, Paulus TVM ^a   van Duijn, Cornelia M ^a   Breteler, Monique MB ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COHORT ANALYSIS; COMORBIDITY; GENETICS; HUMAN; IMAGING; INCIDENCE; INFLAMMATION; MORBIDITY; NEUROLOGIC DISEASE; OXIDATIVE STRESS; PRIORITY JOURNAL;

EID: 33646525733     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(06)70473-2     Document Type: Note

References (66)

1. Oeppen J., and Vaupel J. Broken limits to life expectancy. Science 296 (2002) 1029-1031
2. Peto R., and Doll R. There is no such thing as aging. BMJ 315 (1997) 1030-1032
3. Hofman A., Grobbee D., de Jong P., and van den Ouweland F. Determinants of disease and disability in the elderly: the Rotterdam Study. Eur J Epidemiol 7 (1991) 403-422
4. Bots M., Looman S., Koudstaal P., Hofman A., Hoes A., and Grobbee D. Prevalence of stroke in the general population. Stroke 27 (1996) 1499-1501
5. Bots M., van Wilk E., Koudstaal P., Hofman A., and Grobbee D. Typical and atypical transient ischaemic attacks in the general population: the Rotterdam Study. Stroke 28 (1997) 768-772
6. Ott A., Breteler M., van Harskamp F., et al. Prevalence of Alzheimer's disease and vascular dementia: association with education: the Rotterdam Study. BMJ 310 (1995) 970-973
7. de Rijk M., Breteler M., Graveland G., et al. Prevalence of Parkinson disease in the elderly: the Rotterdam Study. Neurology 45 (1995) 2143-2146
8. Vingerling J., Dielemans I., Hofman A., et al. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology 102 (1995) 205-210
9. Launer L., and Hofman A. Frequency and impact of neurological diseases in the elderly in Europe. Neurology 54 (2000) S1-S40
10. Ferri C., Prince M., Brayne C., et al. Global prevalence of dementia: a Delphi consensus study. Lancet 366 (2005) 2112-2117
11. Barendregt J., and Ott A. Consistency of epidemiologic estimates. Eur J Epidemiol 20 (2005) 827-832
12. Marmot M. Social determinants of health inequalities. Lancet 365 (2005) 1099-1104
13. Ott A., Breteler M., van Harskamp F., Stijnen T., and Hofman A. Incidence and risk of dementia: the Rotterdam Study. Am J Epidemiol 147 (1998) 574-580
14. Klaver C., Assink J., van Leeuwen R., et al. Incidence and progression rates of age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci 42 (2001) 2237-2241
15. van Leeuwen R., Klaver C., Vingerling R., Hofman A., and de Jong P. The risk and natural course of age-related maculopathy: follow-up at 61/2 years in the Rotterdam Study. Arch Ophthalmol 121 (2003) 519-526
16. Hollander M., Koudstaal P., Bots M., Grobbee D., Hofman A., and Breteler M. Incidence, risk, and case fatality of first ever stroke in the elderly population: the Rotterdam Study. J Neurol Neurosurg Psychiatry 74 (2003) 317-321
17. Vermeer S., den Heijer T., Koudstaal P., Oudkerk M., Hofman A., and Breteler M. Incidence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 34 (2003) 392-396
18. de Lau L., Giesbergen P., de Rijk M., Hofman A., Koudstaal P., and Breteler M. Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study. Neurology 63 (2004) 1240-1244
19. Vermeer S., Koudstaal P., Oudkerk M., Hofman A., and Breteler M. Prevalence and risk factors of silent brain infarcts in the population based Rotterdam Scan Study. Stroke 33 (2002) 21-25
20. Hollander M., Bots M., Iglesias del Sol A., et al. Carotid plaques increase the risk of stroke and subtypes of cerebral infarction in asymptomatic elderly: the Rotterdam Study. Circulation 105 (2002) 2872-2877
21. Bots M., Hoes A., Koudstaal P., Hofman A., and Grobbee D. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 96 (1997) 1432-1437
22. Vermeer S., Prins N., den Heijer T., Hofman A., Koudstaal P., and Breteler M. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 348 (2003) 1215-1222
23. de Groot J., de Leeuw F., Oudkerk M., et al. Cerebral white matter lesions and cognitive function: the Rotterdam Scan Study. Ann Neurol 47 (2000) 145-151
24. de Groot J., de Leeuw F., Oudkerk M., Hofman A., Jolles J., and Breteler M. Cerebral white matter lesions and depressive symptoms in elderly adults. Arch Gen Psychiatry 57 (2000) 1071-1076
25. de Groot J., de Leeuw F., Oudkerk M., et al. Periventricular cerebral white matter lesions predict rate of cognitive decline. Ann Neurol 52 (2002) 335-341
26. Vliegenthart R., Hollander M., Breteler M., et al. Stroke is associated with coronary calcification as detected by electron-beam CT: the Rotterdam Coronary Calcification Study. Stroke 33 (2002) 462-465
27. Prins N., van Dijk E., den Heijer T., et al. Cerebral white matter lesions and the risk of dementia. Arch Neurol 61 (2004) 1531-1534
28. Tiemeier H., van Dijck W., Hofman A., Witteman J., Stijnen T., and Breteler M. Relationship between atherosclerosis and late-life depression: the Rotterdam Study. Arch Gen Psychiatry 61 (2004) 369-376
29. Goate A., Chartier-Harlin M., Mullan M., et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349 (1991) 704-706
30. Hendriks L., van Duijn C., Cras P., et al. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene. Nat Genet 1 (1992) 218-221
31. van Duijn C., Hendriks L., Cruts M., Hardy J., Hofman A., and van Broeckhoven C. Amyloid precursor protein gene mutation in early-onset Alzheimer's disease. Lancet 337 (1991) 978
32. Klein R., Zeiss C., Chew E., et al. Complement factor H polymorphism in age-related macular degeneration. Science 308 (2005) 385-389
33. Edwards A., Ritter R., Abel K., Manning A., Panhuysen C., and Farrer L. Complement factor H polymorphism and age-related macular degeneration. Science 308 (2005) 421-424
34. Haines J., Hauser H., Schmidt S., et al. Complement factor H increases the risk of age-related macular degeneration. Science 308 (2005) 419-421
35. Kraepelin E. Memoirs (1987), Springer Verlag, Berlin
36. Bots M., Breteler M., Hofman A., et al. Cerebral white matter lesions and atherosclerosis in the Rotterdam Study. Lancet 341 (1993) 1232-1237
37. Breteler M., Claus J., Grobbee D., and Hofman A. Cardiovascular disease and the distribution of cognitive function in an elderly population: the Rotterdam Study. BMJ 308 (1994) 1604-1608
38. Hofman A., Ott A., Breteler M., et al. Atherosclerosis, apolipoprotein E and the prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 349 (1997) 151-154
39. Stolk R., Breteler M., Ott A., et al. Insulin and cognitive function in an elderly population: the Rotterdam Study. Diabetes Care 5 (1997) 792-795
40. Ott A., Stolk R., van Harskamp F., Pols H., Hofman A., and Breteler M. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 53 (1999) 1937-1942
41. Kalmijn S., Janssen J., Pols H., Lamberts S., and Breteler M. A prospective study on circulating insulin-like growth factor I (IGF-I), IGF-binding proteins, and cognitive function in the elderly. J Clin Endocrinol Metab 85 (2000) 4551-4555
42. de Leeuw F., de Groot J., Oudkerk M., et al. A follow-up study of blood pressure and cerebral white matter lesions. Ann Neurol 46 (1999) 827-833
43. Engelhart M., Geerlings M., Ruitenberg A., et al. Dietary intake of antioxidants and risk of Alzheimer's disease: the Rotterdam Study. JAMA 287 (2002) 3223-3229
44. Prins N., den Heijer T., Hofman A., et al. Homocysteine and cognitive function in the elderly: the Rotterdam Scan Study. Neurology 59 (2002) 1375-1380
45. Kalmijn S., Launer L., Lindemans J., Bots J., Hofman A., and Breteler M. Total homocysteine and cognitive decline in a community-based sample of elderly subjects: the Rotterdam Study. Am J Epidemiol 150 (1999) 283-289
46. Vermeer S., van Dijk E., Koudstaal P., et al. Homocysteine, silent brain infarcts, and white matter lesions: the Rotterdam Scan Study. Ann Neurol 51 (2002) 285-289
47. Ott A., Slooter A., Hofman A., et al. Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study. Lancet 351 (1998) 1840-1843
48. Ruitenberg A., van Swieten J., Witteman J., et al. Alcohol consumption and risk of dementia: the Rotterdam Study. Lancet 359 (2002) 281-286
49. Orgogozo J., Bartigues J., Lafont S., et al. Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area. Rev Neurol (Paris) 153 (1997) 185-192
50. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 340 (1999) 115-126
51. van der Meer I., de Maat M., Hak A., et al. C-reactive protein predicts progression of atherosclerosis measured at various sites in the arterial tree: the Rotterdam Study. Stroke 33 (2002) 2750-2755
52. Engelhart M., Geerlings M., Meijer J., et al. Inflammatory proteins in plasma and the risk of dementia: the Rotterdam Study. Arch Neurol 61 (2004) 668-672
53. 2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 111 (2005) 570-575
54. 2 is associated with risk of dementia. Ann Neurol 59 (2006) 139-144
55. Andersen K., Launer L., Ott A., Hoes A., Breteler M., and Hofman A. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study. Neurology 45 (1995) 1441-1445
56. in t' Veld B., Ruitenberg A., Hofman A., et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 345 (2001) 1515-1521
57. Jama J., Launer L., Witteman J., et al. Dietary antioxidants and cognitive function in a population-based sample of older pesons: the Rotterdam Study. Am J Epidemiol 144 (1996) 275-280
58. de Rijk M., Breteler M., den Breeijen J., et al. Dietary antioxidants and Parkinson's disease: the Rotterdam Study. Arch Neurol 54 (1997) 762-765
59. Vokó Z., Hollander M., Hofman A., Koudstaal P., and Breteler M. Dietary antioxidants and the risk of ischemic stroke: the Rotterdam Study. Neurology 61 (2003) 1273-1275
60. Engelhart M., Geerlings M., Ruitenberg A., et al. Dietary intake of antioxidants and risk of Alzheimer's disease: the Rotterdam Study. JAMA 287 (2002) 3223-3229
61. van Leeuwen R., Boekhoorn S., Vingerling J., et al. Dietary intake of anti-oxidants and risk of age-related macular degeneration: the Rotterdam Study. JAMA 294 (2005) 3101-3107
62. Geerlings M., Ruitenberg A., Witteman J., et al. Reproductive period and risk of dementia in postmenopausal women. JAMA 285 (2001) 1475-1481
63. Geerlings M., Launer L., de Jong F., et al. Endogenous estradiol and risk of dementia in women and men: the Rotterdam Study. Ann Neurol 53 (2003) 607-615
64. den Heijer T., Geerlings M., Hofman A., et al. Higher estrogen levels are not associated with larger hippocampi and better memory performance. Arch Neurol 60 (2003) 213-220
65. Shumaker S., Legault C., Kuller L., et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women. JAMA 291 (2004) 2947-2958
66. Ikram MK, Vingerling JR, Hofman A, Breteler MMB, de Jong PTVM. Aging macular disease in relation to Alzheimer's disease and brain atrophy. Am J Epidemiol (in press).